Revised standards for the treatment of type 2 diabetes in Texas [4]

Diabetes Care

Volumn 22, Issue 7, 1999, Pages 1219-1220

  Davidson, Jaime ^a,b  

^a TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

^b Dallas Diabetes and Endocrine Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; METFORMIN; SULFONYLUREA;

ALGORITHM; CLINICAL PATHWAY; GLUCOSE BLOOD LEVEL; HUMAN; LETTER; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; PRACTICE GUIDELINES; TEXAS;

EID: 0033051754     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.22.7.1219     Document Type: Letter

References (5)

1. Davidson JA: The treatment of type II diabetes in Texas: current issues for managed care and employers. Diabetes Care 20: 446-451, 1997
2. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 21 (Suppl. 1):S23-S31, 1998
3. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 21 (Suppl. 1):S20-S22, 1998
4. UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
5. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998